ICRA and Suzuki Motor project high growth auto market

Bhagyashree Vivarekar / 14 Mar 2017

ICRA and Suzuki Motor project high growth auto market

As per ICRA, the two-wheeler industry is expected to report better demand in FY2018 (volume growth of 8-10 per cent) as against estimated growth of about 7-8 per cent in FY2017.

As per ICRA, the two-wheeler industry is expected to report better demand in FY2018 (volume growth of 8-10 per cent) as against estimated growth of about 7-8 per cent in FY2017. ICRA expects demand to be driven by structural factors such as favourable demographic profile, growing middle class and urbanisation, besides moderate penetration levels. Further, exports are expected to clock growth of 8-10 per cent CAGR over the next three years with a gradual pick up from H2FY18 as key markets are showing signs of a recovery. Key players such as Hero Motocorp, Bajaj Auto and TVS Motors are expected to benefit from this growth.

On the other side, Suzuki Motor Corporation (SMC) expects India to grow into the third-biggest car market in the world and to strengthen its presence it aims to launch 15 new models by 2020. Maruti Suzuki India has already started operations at its new plant in Gujarat and plans to raise its total production to 2 million units by 2020 as against the current capacity of 1.5 million units annually. In FY18 Maruti Suzuki plans to introduce four new products.

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.